TESARO, Inc. (NASDAQ:TSRO) – Equities research analysts at Wedbush boosted their Q3 2017 EPS estimates for TESARO in a report issued on Wednesday. Wedbush analyst D. Nierengarten now forecasts that the biopharmaceutical company will post earnings of ($0.52) per share for the quarter, up from their previous forecast of ($1.65). Wedbush has a “Outperform” rating and a $168.00 price objective on the stock. Wedbush also issued estimates for TESARO’s Q4 2017 earnings at ($2.32) EPS, FY2017 earnings at ($8.20) EPS, Q1 2018 earnings at ($1.56) EPS, Q2 2018 earnings at ($1.26) EPS, Q3 2018 earnings at ($0.92) EPS, Q4 2018 earnings at ($0.57) EPS, FY2018 earnings at ($4.31) EPS, FY2019 earnings at $1.75 EPS, FY2020 earnings at $8.83 EPS and FY2021 earnings at $14.74 EPS.
TSRO has been the topic of a number of other research reports. Gabelli initiated coverage on shares of TESARO in a report on Friday, July 7th. They issued a “buy” rating and a $175.00 price objective on the stock. Oppenheimer Holdings, Inc. initiated coverage on shares of TESARO in a report on Thursday, May 25th. They issued an “outperform” rating and a $183.00 price objective on the stock. ValuEngine upgraded shares of TESARO from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. Credit Suisse Group set a $198.00 price objective on shares of TESARO and gave the stock a “buy” rating in a report on Wednesday, July 19th. Finally, Cowen and Company restated a “market perform” rating and issued a $145.00 price objective on shares of TESARO in a report on Sunday, April 23rd. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $176.35.
TESARO (TSRO) opened at 111.85 on Friday. TESARO has a 12 month low of $83.26 and a 12 month high of $192.94. The company has a 50-day moving average of $130.46 and a 200 day moving average of $149.15. The company’s market cap is $6.06 billion.
TESARO (NASDAQ:TSRO) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.52) by $0.30. TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The business had revenue of $29.50 million during the quarter, compared to the consensus estimate of $18.61 million. During the same period in the previous year, the business posted ($1.28) EPS. TESARO’s revenue was down 17.6% compared to the same quarter last year.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Hanseatic Management Services Inc. increased its position in shares of TESARO by 0.3% in the second quarter. Hanseatic Management Services Inc. now owns 5,936 shares of the biopharmaceutical company’s stock worth $830,000 after buying an additional 15 shares during the period. Teacher Retirement System of Texas increased its position in shares of TESARO by 2.1% in the first quarter. Teacher Retirement System of Texas now owns 2,945 shares of the biopharmaceutical company’s stock worth $453,000 after buying an additional 60 shares during the period. Profund Advisors LLC increased its position in shares of TESARO by 3.8% in the first quarter. Profund Advisors LLC now owns 2,562 shares of the biopharmaceutical company’s stock worth $394,000 after buying an additional 93 shares during the period. Stephens Inc. AR increased its position in shares of TESARO by 6.5% in the second quarter. Stephens Inc. AR now owns 1,874 shares of the biopharmaceutical company’s stock worth $262,000 after buying an additional 115 shares during the period. Finally, State Board of Administration of Florida Retirement System increased its position in shares of TESARO by 0.9% in the first quarter. State Board of Administration of Florida Retirement System now owns 16,740 shares of the biopharmaceutical company’s stock worth $2,576,000 after buying an additional 150 shares during the period.
In related news, VP Edward C. English sold 8,500 shares of the stock in a transaction that occurred on Tuesday, June 6th. The shares were sold at an average price of $138.65, for a total transaction of $1,178,525.00. Following the transaction, the vice president now owns 5,396 shares in the company, valued at $748,155.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 40.50% of the stock is owned by corporate insiders.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.